196 related articles for article (PubMed ID: 35406435)
1. The Long Non-Coding RNA
Abildgaard C; do Canto LM; Rainho CA; Marchi FA; Calanca N; Waldstrøm M; Steffensen KD; Rogatto SR
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406435
[TBL] [Abstract][Full Text] [Related]
2. LncRNA SNHG12 accelerates the progression of ovarian cancer via absorbing miRNA-129 to upregulate SOX4.
Sun D; Fan XH
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2345-2352. PubMed ID: 30964158
[TBL] [Abstract][Full Text] [Related]
3. MiRNA-mRNA integrative analysis reveals epigenetically regulated and prognostic miR-103a with a role in migration and invasion of carboplatin-resistant ovarian cancer cells that acquired mesenchymal-like phenotype.
Pernar Kovač M; Tadić V; Kralj J; Milković Periša M; Orešković S; Babić I; Banović V; Zhang W; Culig Z; Brozovic A
Biomed Pharmacother; 2023 Oct; 166():115349. PubMed ID: 37634476
[TBL] [Abstract][Full Text] [Related]
4. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis.
Liu T; Shen J; He Q; Xu S
Front Genet; 2022; 13():814291. PubMed ID: 35237300
[TBL] [Abstract][Full Text] [Related]
6. A gene signature driven by abnormally methylated DEGs was developed for TP53 wild-type ovarian cancer samples by integrative omics analysis of DNA methylation and gene expression data.
Zhou Z; Jin H; Xu J
Ann Transl Med; 2023 Jan; 11(1):20. PubMed ID: 36760264
[TBL] [Abstract][Full Text] [Related]
7. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
8. Profile and validation of dysregulated long non‑coding RNAs and mRNAs in ovarian cancer.
Lu YM; Wang Y; Liu SQ; Zhou MY; Guo YR
Oncol Rep; 2018 Nov; 40(5):2964-2976. PubMed ID: 30132558
[TBL] [Abstract][Full Text] [Related]
9. A Potential Immune-Related Long Non-coding RNA Prognostic Signature for Ovarian Cancer.
Pan X; Bi F
Front Genet; 2021; 12():694009. PubMed ID: 34367253
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
11. lncRNA small nucleolar RNA host gene 12 promotes renal cell carcinoma progression by modulating the miR‑200c‑5p/collagen type XI α1 chain pathway.
Xu C; Liang H; Zhou J; Wang Y; Liu S; Wang X; Su L; Kang X
Mol Med Rep; 2020 Nov; 22(5):3677-3686. PubMed ID: 32901847
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
Zheng J; Guo J; Cao B; Zhou Y; Tong J
Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
[TBL] [Abstract][Full Text] [Related]
13. Identification of oncogenic long noncoding RNA SNHG12 and DUXAP8 in human bladder cancer through a comprehensive profiling analysis.
Jiang B; Hailong S; Yuan J; Zhao H; Xia W; Zha Z; Bin W; Liu Z
Biomed Pharmacother; 2018 Dec; 108():500-507. PubMed ID: 30243082
[TBL] [Abstract][Full Text] [Related]
14. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
15. Four Prognosis-Associated lncRNAs Serve as Biomarkers in Ovarian Cancer.
Zheng J; Guo J; Zhang H; Cao B; Xu G; Zhang Z; Tong J
Front Genet; 2021; 12():672674. PubMed ID: 34367239
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.
Zhang C; Ren X; Zhang W; He L; Qi L; Chen R; Tu C; Li Z
Bioengineered; 2020 Dec; 11(1):1112-1123. PubMed ID: 33124951
[TBL] [Abstract][Full Text] [Related]
17. High-dimensional deconstruction of ovarian cancer at single-cell precision reveals HEBP2 that reshape the TIME and drive carboplatin resistance.
Yang B; Dai M
Transl Oncol; 2024 Jun; 44():101917. PubMed ID: 38554571
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA SNHG12 promotes immune escape of ovarian cancer cells through their crosstalk with M2 macrophages.
Qian M; Ling W; Ruan Z
Aging (Albany NY); 2020 Sep; 12(17):17122-17136. PubMed ID: 32927431
[TBL] [Abstract][Full Text] [Related]
19. Dynamic TF-lncRNA Regulatory Networks Revealed Prognostic Signatures in the Development of Ovarian Cancer.
Guo Q; Wang J; Gao Y; Li X; Hao Y; Ning S; Wang P
Front Bioeng Biotechnol; 2020; 8():460. PubMed ID: 32478062
[TBL] [Abstract][Full Text] [Related]
20. An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells.
Vera O; Rodriguez-Antolin C; de Castro J; Karreth FA; Sellers TA; Ibanez de Caceres I
Epigenetics; 2018; 13(3):251-263. PubMed ID: 29436261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
